Literature DB >> 29697273

Impact of pathological features of brain metastases in prognosis.

Carlos A Castaneda1,2, Miluska Castillo3, Luis A Bernabe3, Joselyn Sanchez3, Sandro Casavilca4, Pamela García-Corrochano5, Jaime Ponce3, Maria R Villa-Robles4, Carolina Belmar Lopez3, Enrique Orrego5.   

Abstract

AIM: To evaluate the prognostic value of tumor-infiltrating lymphocytes (TILs) and Ki67 in brain metastasis lesions, and the effect of adding them to variables of graded prognostic assessment score. PATIENTS &
METHODS: Clinicopathological information from 111 medical charts of brain metastasis patients was obtained, and TIL distribution (n = 84), Ki67 index (n = 79) and CD3 TIL (n = 64) were prospectively evaluated.
RESULTS: Most frequent TIL pattern was perivascular (67.8%), and median Ki67 and CD3 TIL percents were 30 and 4.8%, respectively. Ki67 ≥15 was associated with shorter survival (p = 0.018) but CD3 TIL was not (p = 0.870). The highest graded prognostic assessment score was not associated with survival (p = 0.648), however, those with low Ki67 and high score was associated with better outcome (p = 0.007).
CONCLUSION: High Ki67 index in brain metastasis carries a worse prognosis.

Entities:  

Keywords:  brain metastasis; infiltrating lymphocytes; proliferation index; survival

Mesh:

Substances:

Year:  2018        PMID: 29697273     DOI: 10.2217/bmm-2017-0161

Source DB:  PubMed          Journal:  Biomark Med        ISSN: 1752-0363            Impact factor:   2.851


  2 in total

1.  Differentiation of brain metastases originating from lung and breast cancers using apparent diffusion coefficient histogram analysis and the relation of histogram parameters with Ki-67.

Authors:  Mustafa Bozdağ; Ali Er; Sümeyye Ekmekçi
Journal:  Neuroradiol J       Date:  2021-10-05

Review 2.  Next-generation immunotherapies for brain metastatic cancers.

Authors:  María López Vázquez; Wanlu Du; Nobuhiko Kanaya; Yohei Kitamura; Khalid Shah
Journal:  Trends Cancer       Date:  2021-03-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.